CoChat
Sign Up
Cited by 122Health Systems, Economic Evaluations, Quality of LifeSchizophrenia research and treatmentEconomic and Environmental Valuation

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation

Open access
Briggs, Andrew, Wild, Diane, Lees, Michael, Reaney, Matthew, Dursun, Serdar, Parry, David, Mukherjee, Jayanti·2008·Health and Quality of Life Outcomes
DOI 10.1186/1477-7525-6-105PMC PMC2613374
Open this paper in CoChat — free accountOpen PDF

Abstract

OBJECTIVE: To examine the impact of schizophrenia, its treatment and treatment-related adverse events related to antipsychotics, on quality of life from the perspective of schizophrenia patients and laypersons. METHODS: Health state descriptions for stable schizophrenia, extra pyramidal symptoms (EPS), hyperprolactinemia, diabetes, weight gain and relapse were developed based on a review of the literature and expert opinion. The quality of life impact of each health state was elicited using a time trade-off instrument administered by interview to 49 stable schizophrenia patients and 75 laypersons. Regression techniques were employed to examine the importance of subject characteristics on health-related utility scores. RESULTS: Patients and laypersons completed the interview in similar times. Stable schizophrenia had the highest mean utility (0.87 and 0.92 for laypersons and patients respectively), while relapse (0.48 and 0.60) had the lowest mean utility. Of the treatment-related adverse events, EPS had the lowest mean utility (0.57 and 0.72, respectively). Age, gender and PANSS score did not influence the utility results independently of health state. On average, patient utilities are 0.077 points higher than utilities derived from laypersons, although the ranking was similar between the two groups. CONCLUSION: Events associated with schizophrenia and treatment of schizophrenia can bring about a significant detriment in patient quality of life, with relapse having the largest negative impact. Results indicate that patients with stable schizophrenia are less willing to trade years of life to avoid schizophrenia-related symptoms compared to laypersons. Both sets of respondents showed equal ability to complete the questionnaire.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1477-7525-6-105

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 8

  1. Brazier J, Akehurst R, Brennan A, Dolan P, Claxton K, McCabe C, O'Hagan A, Sculpher MJ: Tsuchyia A. Should patients have a greater role in valuing health states: whose well-being is it anyway? In Sheffield Health Economics Group Discussion Paper Series (Ref: 04/3). University of Sheffield; 2004.
  2. National Institute for Clinical Excellence (NICE): Guide to the methods of technology assessment. London: NICE; 2004.
  3. Willis GB: Cognitive Interviewing: A "How To" Guide. From the short course "Reducing Survey Error through Research on the Cognitive and Decision Processes in Surveys," presented at the Meeting of the American Statistical Association. 1999.
  4. Cummins C, Stevens A, Kisely S: The use of olanzapine as a first and second choice treatment in schizophrenia, West Midlands Development and Evaluation Committee Report, Wessex Institute for Health Research and Development. 1998.
  5. Glennie JL: Pharmacoeconomic evaluations of clozapine in treatment resistant schizophrenia and risperidone in chronic schizophrenia. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1997.
  6. Lee TT, Ziegler JK, Sommi R, Sugar C, Mahmoud R, Lenert LA: Comparison of preferences for health outcomes in schizophrenia among stakeholder groups. Journal of Psychiatric Research 2000, 34: 201–210. 10.1016/S0022-3956(00)00009-1 · DOI
  7. Sevy S, Nathanson K, Schlecter C, Fulop G: Contingency Valuation and Preferences of Health States Associated With Side Effects of Antipsychotic Medications in Schizophrenia. Schizophrenia Bulletin 2001, 27(4):643–651. · DOI
  8. Cardinal Broadcast: Two cases of schizophrenia. An illustrated lecture. DVD 2004. [http://www.mental-health.tv]

Cited by

Sorted by citations

Items 101–121 of 121

Related

See all

Metadata

Authors
Briggs, A., Wild, D., Lees, M., Reaney, M., Dursun, S., Parry, D., & Mukherjee, J.
Affiliations
  • University of Manchester (GB)
  • Bristol-Myers Squibb (United Kingdom) (GB)
Corresponding author
Wild, Diane
ORCID
Venue
Health and Quality of Life Outcomes
Publisher
Springer Science and Business Media LLC
Published
2008-11-28
Volume
6
Issue
1
Pages
105-105
ISSN
1477-7525 (ISSN-L)
DOI
10.1186/1477-7525-6-105
PMC
PMC2613374
OpenAlex
W2168395707
Cited by
122
References
21
Citations by year
2026: 4 · 2025: 1 · 2023: 14 · 2022: 3 · 2021: 8 · 2020: 9 · 2019: 11 · 2018: 5 · 2017: 4 · 2016: 8 · 2015: 8 · 2014: 16 · 2013: 9 · 2012: 7
FWCI
11.51
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Health and Quality of Life Outcomes (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Funders
  • Bristol-Myers Squibb
  • University of Manchester
  • Deakin University
  • University of Toronto
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Environmental Valuation
Keywords
schizophrenia, quality of life, antipsychotic adverse effects, hyperprolactinemia, antipsychotic-induced diabetes, weight gain, relapse, health utility, time trade-off, health state descriptions
MeSH terms
Adolescent, Adult, Aged, England, Female, Humans, Interviews as Topic, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Schizophrenia, Antipsychotic Agents, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review